Molecular Partners AG & NuMeRI, presentation Feb. 2026The Zurich-based developer is increasingly focusing its pipeline on radiopharmaceutical cancer therapies. A recent development agreement with isotope specialist Eckert & Ziegler marks another step in that direction. The collaboration aims to develop and manufacture so-called Radio-DARPin therapeutics, in which targeted protein molecules deliver radioactive isotopes directly to tumours. Early clinical data on the DARPin molecules in combination with radioisotopes suggest targeted tumour localisation. Proof of efficacy, however, is still pending.
Tag Archive for: theranostics
Nuclidium AGBasel-based NUCLIDIUM AG has successfully closed a Series B financing round of CHF 79 million (EUR 84 million) to advance the development of its copper-based radiopharmaceutical platform. The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR, a company of the Intesa Sanpaolo Group.
Tag Archive for: theranostics
ICPOFollowing the outstanding success of its 2nd edition in 2024, which brought together more than 400 participants from around the world, the ICPO Foundation is proud to announce the next ICPO Theranostics Virtual Summit 2026 on November 12 &13, 2026. This must-attend online scientific event will once again unite hundreds of international healthcare professionals, researchers, and industry leaders.
The three Chairs of the ICPO Summit will guide you through this online event and will interact with you live from the ICPO studio: Prof. Richard P. Baum, President of ICPO Academy for Theranostics, Chairman of the Scientific Advisory Board of the ICPO Foundation and Nuclear Medicine Physician at Curanosticum Wiesbaden Germany; Prof. Frederik L. Giesel, University Hospital Duesseldorf, Germany, Co-Chair ICPO Scientific Advisory Board and Prof. Rudolf A. Werner, Head of Nuclear Medicine, LMU Clinic Munich, Germany.
During the ICPO Summit 2026 attendees from around the globe have the opportunity to engage live with the chairs and speakers in an interactive virtual setting. The program features five key Theranostics themes:
- Rising stars in Theranostics – Beyond PSMA and FAP
- Growing space of Alphas – Outlook on untapped potential
- Clinical trials planning – Navigate from hurdles to outcomes
- Leveraging AI in Theranostics – Advancing clinical practice globally
- Recommendations to grow patient access to Theranostics over the next 5 years
The ICPO Summit 2026 is designed for healthcare professionals, researchers, and industry experts involved in the rapidly evolving field of Theranostics and precision oncology committed to advancing innovative diagnostic and therapeutic approaches for cancer care. The event is particularly relevant for nuclear medicine physicians, oncologists, radiologists, radiopharmacists, medical physicists, and clinical researchers seeking to stay informed about the latest developments in Theranostics.
Please have a look at the program and register: ICPO Theranostics Virtual Summit 2026
Contact:
ICPO Foundation
Email: info@icpo.foundation